FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers
FDA continues to alert healthcare professionals and consumers about the risks of 7-hydroxymitragynine.
FDA continues to alert healthcare professionals and consumers about the risks of 7-hydroxymitragynine.
Patients should only obtain Ozempic with a valid prescription through state-licensed pharmacies, according to FDA.
FDA has become aware of reports of adverse events involving compounded topical finasteride products.
Summary of changes to WADA Prohibited List